Synergistic effect of piperine combined with luteolin on anti-non-small cell lung cancer activity in vitro and in LLC tumour-bearing mice: Mechanistic insights from network pharmacology and molecular docking
By: Liangfeng Wang, Yuexing Chang, Yufeng Liu, Ailing Guo, Baorong Wang, Feng Jin and Yun Deng
References
- H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 71(3) (2021) 209–249; https://doi.org/10.3322/caac.21660
- J. J. Shi, Y. C. Chen, C. T. Peng, L. W. Kuang, Z. T. Zhang, Y. K. Li and K. Huang, Advances in targeted therapy against driver mutations and epigenetic alterations in non-small cell lung cancer, Oncologie 24(4) (2022) 613–648; https://doi.org/10.32604/oncologie.2022.027545
- H. Y. Guo, J. Zhang, C. Qin, H. Yan, T. Liu, H. Y. Hu, S. J. Tang, S. J. Tang and H. N. Zhou, Biomarker--targeted therapies in non-small cell lung cancer: Current status and perspectives, Cells 11(20) (2022) Article ID 3200 (24 pages); https://doi.org/10.3390/cells11203200
- L. Ni and L. Nie, Mechanisms of resistance to the third-generation epidermal growth factor recep tor-tyrosine kinase inhibitors in non-small cell lung cancer, Chin. J. Lung Cancer, 21(2) (2018) 110–115; https://doi.org/10.3779/j.issn.1009-3419.2018.02.02
- A. Malhotra, P. Nair and D. K. Dhawan, Study to evaluate molecular mechanics behind synergistic chemopreventive effects of curcumin and resveratrol during lung carcinogenesis, PloS ONE 9(4) (2014) e93820; https://doi.org/10.1371/journal.pone.0093820
- A. Alemi, M. H. Karamallah, M. Sabaghan, S. A. Hosseini, A. Veisi, S. H. Karamallah and M. Farokhifar, Combination drug therapy by herbal nanomedicine prevent multidrug resistance protein 1: Promote apoptosis in lung carcinoma, J. Appl. Biomater. Functional Materials 22 (2024) (15 pages); https://doi.org/10.1177/22808000241235442
- M. T. Zhu, Y. P. Sun, Y. Su, W. Guan, Y. Wang, J. W. Han, S. Wang, B. Y. Yang, Q. H. Wang and H. X. Kuang, Luteolin: A promising multifunctional natural flavonoid for human diseases, Phytother. Res. 38(7) (2024) 3417–3443; https://doi.org/10.1002/ptr.8217
- N. Aziz, M. Y. Kim and J. Y. Cho, Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies, J. Ethnopharmacology 225(2018) 342–358; https://doi.org/10.1016/j.jep.2018.05.019
- H. Slika, H. Mansour, N. Wehbe, S. A. Nasser, R. Iratni, G. Nasrallah, A. Shaito, T. Ghaddar, F. Kobeissy and A. H. Eid, Therapeutic potential of flavonoids in cancer: ROS-mediated mechanisms, Biomed. Pharmacother. 146(2022) Article ID 112442 (18 pages); https://doi.org/10.1016/j.biopha.2021.112442
- M. D. D. Chagas, C. J. M. Tellis, A. R. Silva, M. Brito, A. J. Teodoro, M. D. Elias, S. R. Ferrarini, M. D. Behrens and C. F. Goncalves-de-Albuquerque, Luteolin: A novel approach to fight bacterial infection, Microbial Pathogenesis 204 (2025) Article ID 107519; https://doi.org/10.1016/j.mic-path.2025.107519
- Z. Y. Wang, M. M. Zeng, Z. J. Wang, F. Qin, J. Chen and Z. Y. He, Dietary Luteolin: A narrative review focusing on its pharmacokinetic properties and effects on glycolipid metabolism, J. Agri-cult. Food Chem. 69(5) (2021) 1441–1454; https://doi.org/10.1021/acs.jafc.0c08085
- K. Rakoczy, J. Kaczor, A. Soltyk, N. Szymanska, J. Stecko, J. Sleziak, J. Kulbacka and D. Baczynska, Application of luteolin in neoplasms and nonneoplastic diseases, Int. J. Mol. Sci. 24(21) (2023) Article ID 15995 (34 pages)https://doi.org/10.3390/ijms242115995
- J. Lu, G. L. Li, K. F. He, W. Q. Jiang, C. Xu, Z. Q. Li, H. H. Wang, W. B. Wang, H. Y. Wang, X. D. Teng and L. S. Teng, Luteolin exerts a marked antitumour effect in cMet-overexpressing patient--derived tumour xenograft models of gastric cancer, J. Translat. Med. 13 (2015) Article ID 42 (11 pages); https://doi.org/10.1186/s12967-015-0398-z
- A. K. Pandurangan and N. M. Esa, Luteolin, a bioflavonoid inhibits colorectal cancer through modulation of multiple signaling pathways: A review, Asian Pacific J. Cancer Prev. 15(14) (2014) 5501–5508; https://doi.org/10.7314/apjcp.2014.15.14.5501
- H. T. Wu, J. Lin, Y. E. Liu, H. F. Chen, K. W. Hsu, S. H. Lin, K. Y. Peng, K. J. Lin, C. C. Hsieh and D. R. Chen, Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway, Phytomedicine 81 (2021) Article ID 153437 (12 pages); https://doi.org/10.1016/j.phymed.2020.153437
- J. X. Ma, J. G. Mo, Y. F. Feng, L. Z. Wang, H. Jiang, J. M. Li and C. Jin, Combination of transcriptomic and proteomic approaches helps unravel the mechanisms of luteolin in inducing liver cancer cell death via targeting AKT1 and SRC, Front. Pharmacol. 15 (2024) Article ID 1450847 (19 pages); https://doi.org/10.3389/fphar.2024.1450847
- Z. B. Jiang, W. J. Wang, C. Xu, Y. J. Xie, X. R. Wang, Y. Z. Zhang, J. M. Huang, M. Huang, C. Xie, P. Liu, X. X. Fan, Y. P. Ma, P. Y. Yan, L. Liu, X. J. Yao, Q. B. Wu and E. L. H. Leung, Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumour immunity in KRAS-mutant lung cancer, Cancer Lett. 515 (2021) 36–48; https://doi.org/10.1016/j.canlet.2021.05.019
- G. M. Meng, K. Q. Chai, X. D. Li, Y. Q. Zhu and W. H. Huang, Luteolin exerts pro-apoptotic effect and anti-migration effects on A549 lung adenocarcinoma cells through the activation of MEK/ERK signaling pathway, Chemico-Biological Interactions 257 (2016) 26–34; https://doi.org/10.1016/j.cbi.2016.07.028
- H. Li, Z. Qiu, W. Xu, X. Chen, D. Wei and Y. Wang, Luteolin inhibits proliferation of lung cancer A549 cells by increasing ROS production and inhibiting the AKT/mTOR signaling pathway and HO-1 expression, Nan Fang Yi Ke Da Xue Xue Bao 44(12) (2024) 2367–2374; https://doi.org/10.12122/j.issn.1673-4254.2024.12.12
- J. Remon, C. E. Steuer, S. S. Ramalingam and E. Felip, Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients, Ann. Oncology 29 (2018) I20-I27; https://doi.org/10.1093/annonc/mdx704
- S. Baldacci, E. J. Brea, F. Facchinetti, Z. Li, K. Ngo, S. Malhotra, M. A. Booker, M. Y. Tolstorukov, S. Chakravarti, C. Hinchey, N. R. Mahadevan, F. Lococo, S. D’Agnelli, L. Gnetti, N. Campanini, A. Leonetti, W. W. Feng, J. A. Tsai, A. V. Hartley, M. A. Locquet, L. Fournel, M. Alifano, A. Mansuet-Lupo, A. Saldanha, W. Haller, L. M. Zasadil, M. Zielinska, K. Bui, B. Tuladhar, P. H. Lizotte, E. V. Ivanova, L. V. Sequist, P. C. Gokhale, C. P. Paweletz, E. L. Smith, P. A. Janne and D. A. Barbie, Eradicating drug tolerant persister cells in EGFR-mutated non-small cell lung cancer by targeting TROP2 with CAR-T cellular therapy, Cancer Discov. 15(11) (2025) 2235–2250; https://doi.org/10.1158/2159-8290.Cd-24-1515
- B. C. Tong, L. Gu, X. F. Wang, D. A. Wigle, J. D. Phillips, D. H. Harpole, Jr., J. A. Klapper, T. Sporn, N. E. Ready and T. A. D’Amico, Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer, J. Thoracic Cardiovasc. Surgery 163(2) (2022) 427–436; https://doi.org/10.1016/j.jtcvs.2021.02.099
- H. Abolhassani, M. S. Safavi, S. Handali, M. Nosrati and S. A. Shojaosadati, Synergistic effect of self-assembled curcumin and piperine co-loaded human serum albumin nanoparticles on suppressing cancer cells, Drug Devel. Ind. Pharm. 46(10) (2020) 1647–1655; https://doi.org/10.1080/03639045.2020.1820032
- M. K. Pal, S. P. Jaiswar, A. K. Srivastav, S. Goyal, A. Dwivedi, A. Verma, J. Singh, A. K. Pathak, P. L. Sankhwar and R. S. Ray, Synergistic effect of piperine and paclitaxel on cell fate via cyt-c, Bax/Bcl-2-caspase-3 pathway in ovarian adenocarcinomas SKOV-3 cells, Eur. J. Pharmacol. 791 (2016) 751–762; https://doi.org/10.1016/j.ejphar.2016.10.019
- D. Chen, Y. M. Ma, Z. Y. Guo, L. Liu, Y. R. Yang, Y. R. Wang, B. N. Pan, L. Y. Wu, Y. Y. Hui and W. J. Yang, Two natural alkaloids synergistically induce apoptosis in breast cancer cells by inhibiting STAT3 activation, Molecules 25(1) (2020) Article ID 216 (16 pages); https://doi.org/10.3390/molecules25010216
- M. K. Manickasamy, A. Kumar, B. Bharathwajchetty, M. S. Alqahtani, M. Abbas, A. Alqahtani, J. Unnikrishnan, A. Bishayee, G. Sethi and A. B. Kunnumakkara, Synergistic enhancement: Exploring the potential of piperine in cancer therapeutics through chemosensitization and combination therapies, Life Sci. 354 (2024) Article ID 122943; https://doi.org/10.1016/j.lfs.2024.122943
- Y. Liu, X. Li, C. Chen, N. Ding, S. Ma and M. Yang, Exploration of compatibility rules and discovery of active ingredients in TCM formulas by network pharmacology, Chin. Herb. Med. 16(4) (2024) 572–588; https://doi.org/10.1016/j.chmed.2023.09.008
- R. Jakhar, M. Dangi, A. Khichi and A. K. Chhillar, Relevance of molecular docking studies in drug designing, Curr. Bioinformatics 15(4) (2020) 270–278; https://doi.org/10.2174/1574893615666191219094216
- X. Li, J. Sun, X. Li, Y. Dai, C. Zhao, S. Man, Y. Wang and W. Gao, Dioscin-6’-O-acetate impairs migration of lung cancer cells through attenuations of MMP-2 and MMP-9 via NF-κB suppression, Med. Chem. Res. 28(1) (2019) 1–12; https://doi.org//10.1007/s00044-018-2257-y
- I. Aggarwal, R. B. Aniyery, A. Gupta, H. Kaur, Megha, Diksha and S. Sudheer, Anticancer and Antimicrobial Studies of Dibutyl(hexadecanoyloxy)stannyl Hexadecanoate, in Emerging Trends in Synthesis and Catalysis, Springer, New York 2023, pp. 13–33.
- A. H. Jumaa, I. M. Hade, K. N. Abdulla and Y. S. Yasin, Ciprofloxacin and metformin as dual therapeutic agents: Synergistic impact on cervical cancer cell line proliferation: Insight into cytoplasmic SRC tyrosine kinase targeting, Asian Pacific J. Cancer Biol. 10(3) (2025) 699–712; https://doi.org/10.31557/apjcb.2025.10.3.699-712
- T. C. Chou, Drug combination studies and their synergy quantification using the Chou-Talalay method, Cancer Res. 70(2) (2010) 440–446; https://doi.org/10.1158/0008-5472.Can-09-1947
- F. D. Prieto-Martínez, M. Arciniega and J. L. Medina-Franco, Molecular docking: Current advances and challenges, TIP Revista Especializada en Ciencias Químico-Biológicas 21(suppl 1) (2018) 65–87; https://doi.org/10.22201/fesz.23958723e.2018.0.143
- A. Sailapathi, G. Murugan, K. Somarathinam, S. Gunalan, R. Jagadeesan, N. Yoosuf, S. Kanagaraj and G. Kothandan, Proposing the promiscuous protein structures in JNK1 and JNK3 for virtual screening in pursuit of potential leads, ACS Omega 5(8) (2020) 3969–3978; https://doi.org/10.1021/acsomega.9b03458
- S. Vilar, G. Cozza and S. Moro, Medicinal chemistry and the molecular operating environment (MOE): Application of QSAR and molecular docking to drug discovery, Curr. Topics Med. Chem. 8(18) (2008) 1555–1572; https://doi.org/10.2174/156802608786786624
- G. Wu, D. H. Robertson, C. L. Brooks, 3rd and M. Vieth, Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm, J. Comput. Chem. 24(13) (2003) 1549–1562; https://doi.org/10.1002/jcc.10306
- S. Gautam, In silico drug development against RNA dependent RNA polymerase of SARS-CoV-2, M.Sc. Thesis, Central Department of Biotechnology, Tribhuvan University, Kirtipur, Kathmandu, Nepal, 2023; https://hdl.handle.net/20.500.14540/23764
- J. F. Zhang, B. Aray, Y. Zhang, Y. L. Bai, T. Yuan, S. L. Ding, Y. Y. Xue, X. L. Huang and Z. Y. Li, Synergistic effect of cucurbitacin E and myricetin on anti-non-small cell lung cancer: Molecular mechanism and therapeutic potential, Phytomedicine 111 (2023) Article ID 154619; https://doi.org/10.1016/j.phymed.2022.154619
- Q. Zhang, Y. Zhou, X. Y. Feng, Y. Gao, C. Z. Huang and X. Q. Yao, Low-dose orlistat promotes the therapeutic effect of oxaliplatin in colorectal cancer, Biomed. Pharmacother. 153 (2022) Article ID 113426 (12 pages); https://doi.org/10.1016/j.biopha.2022.113426
- Y. Lin, J. P. Xu, H. H. Liao, L. Li and L. Pan, Piperine induces apoptosis of lung cancer A549 cells via p53-dependent mitochondrial signaling pathway, Tumour Biol. 35(4) (2014) 3305–3310; https://doi.org/10.1007/s13277-013-1433-4
- X. T. Cai, T. M. Ye, C. Liu, W. G. Lu, M. Lu, J. Zhang, M. Wang and P. Cao, Luteolin induced G2 phase cell cycle arrest and apoptosis on non-small cell lung cancer cells, Toxicol. in Vitro 25(7) (2011) 1385–1391; https://doi.org/10.1016/j.tiv.2011.05.009
- T. C. Chou, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol. Rev. 58(3) (2006) 621–681; https://doi.org/10.1124/pr.58.3.10
- Y. R. Wang, J. J. Xiao, X. M. Dong, S. C. Meng, S. J. Deng, B. Kuang, J. Yan, F. Zhao and H.-H. Zeng, The antitumour activity of Shuang-Xi-Zuo-Wan-1 in C57/BL mice, J. Peking University Health Sciences 37(4) (2005) 421–424.
- A. H. Fischer, K. A. Jacobson, J. Rose and R. Zeller, Hematoxylin and eosin staining of tissue and cell sections, Cold Spring Harb. Protoc. 2008 (2008) pdb.prot4986; https://doi.org/10.1101/pdb.prot4986
- X. F. Li, S. X. Ren, C. Zhao, J. Y. Li, G. H. Yang, W. He and C. C. Zhou, Quantitative test of mutant EGFR and its effect on efficacy of EGFR TKI in advanced NSCLC, J. Thorac Oncol. 8 (2013) S787–S787; https://doi.org/10.1200/jco.2013.31.15_suppl.e22186
- M. W. Lee, D. S. Kim, N. Y. Min and H. T. Kim, Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin, Int. J. Cancer 122(10) (2008) 2380–2384; https://doi.org/10.1002/ijc.23371
- H. Cheng, M. Shcherba, G. Pendurti, Y. Liang, B. Piperdi and R. Perez-Soler, Targeting the PI3K/AKT/mTOR pathway: Potential for lung cancer treatment, Lung Cancer Manag. 3(1) (2014) 67–75; https://doi.org/10.2217/lmt.13.72
- D. Gfeller, A. Grosdidier, M. Wirth, A. Daina, O. Michielin and V. Zoete, SwissTargetPrediction: A web server for target prediction of bioactive small molecules, Nucleic Acids Res. 42(W1) (2014) W32-W38; https://doi.org/10.1093/nar/gku293
- M. Karadag-Alpaslan, Molecular Docking, in International Studies and Evaluations in the Field of Health Sciences, (Ed. H. Akgül, E. Şahna, Z. Selamoğlu), Chapter 8, Ondokuz Mayis University, Samsun 2024, pp. 105–113.
- W. L. Shang, C. H. Lai, S. W. Luo and L. M. Chen, Murine models of lung adenocarcinoma: Valuable tools for preclinical investigation, Gene 971 (2025) Article ID 149802; https://doi.org/10.1016/j.gene.2025.149802
- N. Lonberg, The problem with syngeneic mouse tumour models, Cancer Immunol. Res. 13(4) (2025) 456–462; http://doi.org/10.1158/2326-6066.Cir-24-1046
- P. K. Sahu, A. Sharma, S. Rayees, G. Kour, A. Singh, M. Khullar, A. Magotra, S. K. Paswan, M. Gupta, I. Ahmed, S. Roy, M. Kumar Tikoo, S. L. Sharma, S. Singh and G. Singh, Pharmacokinetic study of piperine in Wistar rats after oral and intravenous administration, Int. J. Drug Deliv. 6(1) (2014) 82–87; http://www.arjournals.org/index.php/ijdd/index
- X. X. Dong, W. Lan, X. B. Yin, C. J. Yang, W. P. Wang and J. Ni, Simultaneous determination and pharmacokinetic study of quercetin, luteolin, and apigenin in rat plasma after oral administration of Matricaria chamomilla L. extract by HPLC-UV, Evidence-Based Complement. Alter. Med. 2017 (2017) Article ID 8370584 (7 pages); https://doi.org/10.1155/2017/8370584
- G. Kumar, B. Ruivinho, T. Virmani, P. Brandao, P. Choudhary, N. Kumar Chouhan, M. Kumar, A. Sharma, M. S. Akhtar, O. Afzal, S. Farooqui, S. O. D. Duarte and P. Fonte, Unlocking the full potential of piperine-loaded nanocarriers for cancer treatment, Therap. Del. 16(9) (2025) 881–901; https://doi.org/10.1080/20415990.2025.2542107
Language: English
Page range: 1 - 26
Accepted on: May 25, 2026
Published on: Jun 30, 2026
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2026 Liangfeng Wang, Yuexing Chang, Yufeng Liu, Ailing Guo, Baorong Wang, Feng Jin, Yun Deng, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.